Keyphrases
18F-FLT
16%
18F-labeled
11%
5-HT2A Receptor
51%
5-HT2A Receptor Agonist
13%
Active Sites
33%
AE105
51%
Aldehydes
11%
Angiogenesis
27%
C(RGDyK)
17%
Cancer Xenograft
23%
Cortisol Awakening Response
11%
Dosimetry
17%
Dynamic PET
13%
First-in-human
14%
First-in-human Study
12%
Fluorine-18
12%
Gallium-68
33%
Human Cancer
12%
Human Xenografts
23%
In Vivo Evaluation
16%
In Vivo Imaging
15%
Integrin
15%
Lutetium-177 (177Lu)
11%
Minipig
11%
Mood Disorders
15%
NODAGA
33%
Non-invasive Assessment
13%
Oxime
11%
PET Imaging
27%
PET Tracer
21%
Positron Emission Tomography
78%
Positron Emission Tomography Tracers
29%
Positron Emission Tomography-computed Tomography (PET-CT)
24%
Prostate Cancer
13%
Radioligand
22%
Radiosynthesis
17%
Receptor Agonist
11%
Receptor Binding
58%
Serotonergic System
16%
Serotonin 2A
13%
Serotonin 2A Receptor (5-HT2AR)
46%
Serotonin Transporter
39%
Serum Serotonin
12%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
67%
Tissue Factor
32%
Tissue Factor Expression
21%
Tracer Uptake
18%
Tumor
20%
Tumor Uptake
20%
Xenograft Tumor
19%
Medicine and Dentistry
Angiogenesis
24%
Biodistribution
10%
Biological Marker
13%
Breast Cancer
6%
Cancer Cell
7%
Carboplatin
5%
Castration Resistant Prostate Cancer
5%
Cell Proliferation
8%
Clinical Trial
10%
Copper 64
22%
Diagnosis
7%
Dosimetry
19%
Factor VII
16%
Fluorine-18
39%
Fluorodeoxyglucose F 18
11%
Gallium 68
19%
Gene Expression
9%
General Anesthesia
5%
Gleason Score
5%
Glioblastoma
12%
Human Study
12%
In Vitro
7%
Integrin
16%
Lutetium 177
11%
Malignant Neoplasm
14%
Metastatic Carcinoma
11%
Molecular Imaging
6%
Motor Performance
5%
Myocardial Infarction
11%
Neoplasm
62%
Neuroendocrine Tumor
11%
Ovarian Cancer
11%
Patient Monitoring
6%
Peptide Receptor
5%
Positron Emission Tomography
100%
Positron Emission Tomography
44%
Positron Emission Tomography - Magnetic Resonance Imaging
6%
Positron Emission Tomography-Computed Tomography
20%
Primary Tumor
8%
Prostate Cancer
17%
Radioactive Tracer
55%
Radionuclide Therapy
5%
Tetraxetan
36%
Thromboplastin
16%
Treatment Response
7%
Tumor Imaging
6%
Tumor Invasion
17%
Tumor Xenograft
44%
Urokinase Receptor
56%
Xenograft
13%
Pharmacology, Toxicology and Pharmaceutical Science
Adrenergic Receptor
5%
Azide
8%
Biodistribution
9%
Biological Marker
10%
Blood Clotting Factor 7
24%
Breast Cancer
6%
Bungarotoxin Receptor
5%
Carbon 11
28%
Carboplatin
5%
Chemotherapy
5%
Clinical Trial
8%
Copper 64
22%
Daporinad
5%
Dosimetry
15%
Fluorine 18
45%
Fluorodeoxyglucose F 18
5%
Gallium 68
18%
Glioblastoma
6%
Guanosine Phosphate
5%
Heart Infarction
11%
Human Study
12%
Infarction
5%
Integrin
18%
Malignant Neoplasm
30%
Metastasis
6%
Minipig
11%
Mouse
19%
Neoplasm
68%
Neuroendocrine Tumor
11%
Nicotinamide Phosphoribosyltransferase
5%
Oxime
11%
Paclitaxel
5%
Pancreas Cancer
5%
Phenethylamine Derivative
5%
Primary Tumor
8%
Proline
5%
Prostate Cancer
12%
Radiation Exposure
7%
Radioligand
24%
Radiopharmaceutical Agent
7%
Receptor
10%
Receptor Agonist
16%
Safety Assessment
8%
Serotonin 2A Agonist
5%
Tetraxetan
13%
Thromboplastin
32%
Tracer
60%
Trastuzumab
5%
Tumor Invasion
5%
Urokinase Receptor
33%
